Vanda is kicking off a phase 3 trial which will evaluate the efficacy and safety of its newly approved motion sickness drug Nereus in patients receiving a high dose of a GLP-1 agonist. The primary endpoint is the proportion of patients
read more
Partnership to develop next‑generation T‑cell engagers for solid tumours More: Oxford BioTherapeutics signs collaboration with Bristol Myers Squibb Source: News
read more
First patient dosed as DOMISOL study grows beyond Australia More: Kainova expands DT 7012 trial into Europe Source: News
read moreSpecialty assets company Garda Therapeutics has acquired Assertio and its chemotherapy supportive care treatment Rolvedon for $125.1 million. In connection with the deal, Assertio has divested the rest of its assets to New Jersey generics and branded drugmaker Cosette Pharmaceuticals
read moreAbbVie is spearheading a new battle in pharma’s long-running fight to reform the federal government’s 340B drug discount program. More: AbbVie challenges 'outdated' 340B drug discount program guidance in new lawsuit Source: fierce
read moreRobert F. Kennedy Jr. is starting a podcast. Unveiling the show on social media, the Department of Health and Human Services (HHS) secretary framed the podcast as a response to public health problems that he said have made “many of
read more© 1994 - 2026 B.M. Pharmaceuticals